UroGen completes bladder cancer phase 3 trial enrollment
UroGen Pharma Ltd. says its phase 3 ENVISION study of investigational agent UGN-102 (mitomycin) for…
December 19, 2022 - 3 minutes
UroGen Pharma Ltd. says its phase 3 ENVISION study of investigational agent UGN-102 (mitomycin) for…